2024-09-22 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis:

**Company Overview:** Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of prescription medicines, vaccines, and animal health products. 

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative return:** MRK (82.41%) has underperformed the S&P 500 (132.46%) over the given timeframe. 
* **Relative Performance:** The current relative divergence of -50.05 indicates that MRK's performance has been lagging behind the S&P 500 by approximately 33.59% (as measured by the relative divergence compared to historical values).

**2. Recent Price Movement:**

* **Current price:** $117.17
* **Moving Averages:**
    * 5-day: $117.84
    * 20-day: $116.86
    * 60-day: $119.52
* **Analysis:** The stock price is currently trading slightly below its 5-day moving average, suggesting a potential short-term downward trend. However, it's above the 20-day moving average, indicating potential for a short-term rebound. The 60-day moving average is above the current price, suggesting a potential longer-term downtrend. 

**3. Technical Indicators:**

* **RSI:** 45.66 - Currently in neutral territory.
* **PPO:** 0.26 -  A slightly positive PPO suggests potential for further price increases.
* **Delta_Previous_Relative_Divergence:** -4.04 - A negative value indicates a potential short-term downward trend. 
* **Expected_Return:** 15.02% - This represents the potential maximum return for a 5-year investment.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue | 
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ | 

* **Analysis:** Recent earnings have been mixed, with some quarters exceeding expectations and others falling short.  The latest earnings report (2024-08-05) showed EPS of 2.15 and revenue of $16.11 billion, exceeding analyst expectations. 

**5. Overall Analysis:**

MRK is a large-cap pharmaceutical company with a consistent history of revenue generation, despite recent underperformance compared to the S&P 500. While the current price action suggests potential short-term weakness, the positive technical indicators and recent strong earnings report suggest a potential for long-term growth. 

**6. Recommendation:**

While MRK has underperformed the market, it's important to consider the long-term potential of this company.  Investors who are looking for a solid dividend payer with growth potential in the pharmaceutical industry could consider investing in MRK.  However, investors should carefully monitor the stock's performance and adjust their positions accordingly based on the changing market conditions and the company's future performance. 
